Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy

Recent advances in cancer treatment have emerged from new immunotherapies targeting T-cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and programmed cell death (PD)-1. In this context, anti-CTLA-4 and anti-PD-1 monoclonal antibodies have demonstrated survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Durgeau, Aurélie, Virk, Yasemin, Corgnac, Stéphanie, Mami-Chouaib, Fathia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786548/
https://www.ncbi.nlm.nih.gov/pubmed/29403496
http://dx.doi.org/10.3389/fimmu.2018.00014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786548/
https://www.ncbi.nlm.nih.gov/pubmed/29403496
http://dx.doi.org/10.3389/fimmu.2018.00014

Ejemplares similares